Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CLDX
- CUSIP: 15117B10
- Web: www.celldextherapeutics.com
Capitalization:- Market Cap: $299.04 million
- Outstanding Shares: 128,341,000
Average Prices:- 50 Day Moving Avg: $2.44
- 200 Day Moving Avg: $2.96
- 52 Week Range: $2.20 - $5.02
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.45
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $9.46 million
- Price / Sales: 31.61
- Book Value: $1.82 per share
- Price / Book: 1.28
Profitability:- EBIDTA: ($115,220,000.00)
- Net Margins: -1,318.94%
- Return on Equity: -51.87%
- Return on Assets: -37.19%
Debt:- Current Ratio: 5.56%
- Quick Ratio: 5.56%
Misc:- Average Volume: 1.75 million shs.
- Beta: 2.75
- Short Ratio: 13.59
Frequently Asked Questions for Celldex Therapeutics (NASDAQ:CLDX)
What is Celldex Therapeutics' stock symbol?
Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."
How were Celldex Therapeutics' earnings last quarter?
Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its earnings results on Tuesday, August, 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.28) by $0.05. The firm earned $3.83 million during the quarter, compared to analyst estimates of $1.21 million. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.87%. The business's revenue was up 175.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.32) EPS. View Celldex Therapeutics' Earnings History.
When will Celldex Therapeutics make its next earnings announcement?
Where is Celldex Therapeutics' stock going? Where will Celldex Therapeutics' stock price be in 2017?
8 brokers have issued twelve-month price objectives for Celldex Therapeutics' stock. Their predictions range from $3.00 to $16.00. On average, they anticipate Celldex Therapeutics' stock price to reach $8.08 in the next twelve months. View Analyst Ratings for Celldex Therapeutics.
What are analysts saying about Celldex Therapeutics stock?
Here are some recent quotes from research analysts about Celldex Therapeutics stock:
- 1. According to Zacks Investment Research, "Celldex’s efforts to build its immuno-oncology pipeline are impressive. Its lead pipeline candidate, glembatumumab vedotin, is in mid-stage development for different types of cancer. Apart from glembatumumab vedotin, Celldex has several promising candidates in its pipeline, including varlilumab. We are also encouraged by Celldex’s partnership agreements with big players like Bristol-Myers. Meanwhile, the recent Kolltan acquisition adds some interesting candidates to the company’s pipeline. However, with no approved product in its portfolio, Celldex has to depend entirely on product development and licensing agreements, contracts and grants for revenues. We are also concerned about the early- to mid-stage nature of its pipeline. Estimates have remained mostly stable lately ahead of the Q2 results. Celldex has a positive record of earnings surprises in the recent quarters. " (7/17/2017)
- 2. Cowen and Company analysts commented, "At ASCO updates on varli and glemba were provided." (6/6/2017)
- 3. Jefferies Group LLC analysts commented, "The PIII METRIC trial evaluating glemba has observed recent patient acceleration due to new EU sites and driving a potential enrollment completion by Sept 2017. Based on this timeline, data could be available in 2Q18, and we remain less optimistic on the success of the trial. In '17, we should receive data from PI portion of varli+nivo." (3/15/2017)
Who are some of Celldex Therapeutics' key competitors?
Some companies that are related to Celldex Therapeutics include Intellia Therapeutics (NTLA), ImmunoGen (IMGN), ANI Pharmaceuticals (ANIP), KALA PHARMCTLS (KALA), Inovio Pharmaceuticals (INO), WAVE Life Sciences (WVE), AC Immune SA (ACIU), Cara Therapeutics (CARA), PDL BioPharma (PDLI), Celyad SA (CYAD), Agenus (AGEN), Concert Pharmaceuticals (CNCE), Adamas Pharmaceuticals (ADMS), Abeona Therapeutics (ABEO), Puretech Health PLC (PRTC), Novavax (NVAX), Codexis (CDXS) and Idera Pharmaceuticals (IDRA).
Who are Celldex Therapeutics' key executives?
Celldex Therapeutics' management team includes the folowing people:
- Larry Ellberger, Independent Chairman of the Board
- Anthony S. Marucci, President, Chief Executive Officer, Director
- Sam Martin, Chief Financial Officer, Senior Vice President
- Tibor Keler Ph.D., Executive Vice President and Chief Scientific Officer
- Thomas Andrew Davis M.D., Executive Vice President and Chief Medical Officer
- Sarah Cavanaugh, Senior Vice President - Corporate Affairs and Administration
- Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
- Theresa M. LaVallee Ph.D., Senior Vice President - Regulatory and Precision Medicine
- Ronald A. Pepin Ph.D., Senior Vice President and Chief Business Officer
- Richard Wright Ph.D., Senior Vice President, Chief Commercial Officer`
Who owns Celldex Therapeutics stock?
Celldex Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.81%), FMR LLC (7.80%), KLP Enterprises LLC (5.49%), Meditor Group Ltd (4.64%), Northern Trust Corp (1.62%) and State Street Corp (1.50%). Company insiders that own Celldex Therapeutics stock include Avery W Catlin, Larry Ellberger and Tibor Keler. View Institutional Ownership Trends for Celldex Therapeutics.
Who sold Celldex Therapeutics stock? Who is selling Celldex Therapeutics stock?
Celldex Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, Federated Investors Inc. PA, Frontier Capital Management Co. LLC, Goldman Sachs Group Inc., New York State Common Retirement Fund, Russell Investments Group Ltd. and Numeric Investors LLC. View Insider Buying and Selling for Celldex Therapeutics.
Who bought Celldex Therapeutics stock? Who is buying Celldex Therapeutics stock?
Celldex Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Meditor Group Ltd, Vanguard Group Inc., Ameriprise Financial Inc., Dimensional Fund Advisors LP, Northern Trust Corp, Teachers Advisors LLC, Virtu KCG Holdings LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Celldex Therapeutics stock in the last two years include Larry Ellberger and Tibor Keler. View Insider Buying and Selling for Celldex Therapeutics.
How do I buy Celldex Therapeutics stock?
Shares of Celldex Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celldex Therapeutics' stock price today?
One share of Celldex Therapeutics stock can currently be purchased for approximately $2.33.
MarketBeat Community Rating for Celldex Therapeutics (NASDAQ CLDX)MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Celldex Therapeutics (NASDAQ:CLDX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 6 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $8.08 (246.92% upside) |
Analysts' Ratings History for Celldex Therapeutics (NASDAQ:CLDX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/9/2017 | HC Wainwright | Set Price Target | Buy | $10.00 | High |  |
| 6/29/2017 | Aegis | Reiterated Rating | Buy | | Medium | |
| 6/6/2017 | Cowen and Company | Reiterated Rating | Buy | | High | |
| 5/11/2017 | Jefferies Group LLC | Reiterated Rating | Hold | $4.00 -> $3.50 | High | |
| 11/10/2016 | Roth Capital | Reiterated Rating | Buy | $7.00 | N/A | |
| 11/8/2016 | Wedbush | Reiterated Rating | Neutral | $3.00 | N/A | |
| 11/8/2016 | Cantor Fitzgerald | Reiterated Rating | Buy | $9.00 | N/A | |
| 10/4/2016 | Brean Capital | Initiated Coverage | Buy | $16.00 | N/A | |
| 3/7/2016 | Leerink Swann | Downgrade | Outperform -> Market Perform | $30.00 -> $4.00 | N/A | |
| 3/7/2016 | Oppenheimer Holdings, Inc. | Downgrade | Outperform -> Market Perform | | N/A | |
| 3/7/2016 | Guggenheim | Downgrade | Buy -> Neutral | | N/A | |
(Data available from 8/22/2015 forward)
Earnings History for Celldex Therapeutics (NASDAQ:CLDX)Earnings History by Quarter for Celldex Therapeutics (NASDAQ CLDX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.27) | | | | | N/A | |
| 8/8/2017 | Q2 2017 | ($0.28) | ($0.23) | $1.21 million | $3.83 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.29) | ($0.28) | $0.57 million | $1.53 million | View | N/A | |
| 3/14/2017 | Q4 2016 | ($0.34) | ($0.30) | $1.10 million | $1.87 million | View | Listen | |
| 11/7/2016 | Q3 2016 | ($0.33) | ($0.29) | $1.09 million | $2.20 million | View | N/A | |
| 8/8/2016 | Q2 | ($0.34) | ($0.32) | $0.96 million | $1.39 million | View | Listen | |
| 5/5/2016 | Q1 16 | ($0.35) | ($0.35) | $1.06 million | $1.30 million | View | N/A | |
| 2/25/2016 | Q415 | ($0.35) | ($0.33) | $0.80 million | $1.80 million | View | Listen | |
| 11/5/2015 | Q3 | ($0.35) | ($0.32) | $1.02 million | $1.03 million | View | N/A | |
| 8/10/2015 | Q215 | ($0.34) | ($0.33) | $0.51 million | $2.18 million | View | Listen | |
| 4/29/2015 | Q115 | ($0.36) | ($0.33) | $0.52 million | $0.49 million | View | N/A | |
| 2/24/2015 | Q314 | ($0.35) | ($0.36) | $0.49 million | $1.50 million | View | N/A | |
| 11/4/2014 | Q3 | ($0.33) | ($0.31) | $0.43 million | $1.10 million | View | N/A | |
| 8/6/2014 | Q214 | ($0.31) | ($0.32) | $0.38 million | $0.60 million | View | N/A | |
| 5/1/2014 | Q1 2014 | ($0.26) | ($0.33) | $0.34 million | $0.40 million | View | N/A | |
| 3/3/2014 | Q413 | ($0.28) | ($0.27) | $0.27 million | $0.62 million | View | N/A | |
| 11/5/2013 | Q313 | ($0.24) | ($0.29) | $0.09 million | $1.00 million | View | N/A | |
| 8/6/2013 | Q2 2013 | ($0.22) | ($0.24) | $1.57 million | $0.97 million | View | N/A | |
| 5/2/2013 | Q1 2013 | ($0.22) | ($0.23) | $2.65 million | $2.41 million | View | N/A | |
| 3/7/2013 | Q4 2012 | ($0.25) | ($0.27) | $2.45 million | $3.65 million | View | N/A | |
| 11/1/2012 | Q312 | ($0.24) | ($0.25) | $2.07 million | $3.11 million | View | N/A | |
| 8/10/2012 | | ($0.25) | ($0.23) | | | View | N/A | |
| 5/3/2012 | | ($0.25) | ($0.27) | | | View | N/A | |
| 3/7/2012 | | ($0.26) | ($0.29) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Celldex Therapeutics (NASDAQ:CLDX)2017 EPS Consensus Estimate: ($1.01)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | ($0.30) | ($0.26) | ($0.28) |
| Q2 2017 | 3 | ($0.27) | ($0.23) | ($0.26) |
| Q3 2017 | 3 | ($0.28) | ($0.20) | ($0.24) |
| Q4 2017 | 3 | ($0.29) | ($0.20) | ($0.24) |
(Data provided by Zacks Investment Research)
Dividend History for Celldex Therapeutics (NASDAQ:CLDX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Celldex Therapeutics (NASDAQ:CLDX)Insider Ownership Percentage: 4.10%
Institutional Ownership Percentage: 63.88%
Insider Trades by Quarter for Celldex Therapeutics (NASDAQ:CLDX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/2/2016 | Tibor Keler | VP | Buy | 3,000 | $3.32 | $9,960.00 | |
| 11/23/2015 | Avery W. Catlin | CFO | Sell | 25,000 | $18.00 | $450,000.00 | |
| 8/25/2015 | Larry Ellberger | Director | Buy | 5,000 | $14.00 | $70,000.00 | |
| 8/20/2015 | Larry Ellberger | Director | Buy | 5,000 | $15.00 | $75,000.00 | |
| 8/18/2015 | Larry Ellberger | Director | Buy | 5,000 | $15.95 | $79,750.00 | |
| 8/13/2015 | Anthony S Marucci | CEO | Buy | 5,800 | $16.81 | $97,498.00 | |
| 8/13/2015 | Larry Ellberger | Director | Buy | 5,000 | $16.59 | $82,950.00 | |
| 6/15/2015 | Avery W Catlin | CFO | Sell | 25,000 | $24.59 | $614,750.00 | |
| 12/6/2013 | Avery Catlin | CFO | Sell | 183,333 | $24.50 | $4,491,658.50 | |
| 12/6/2013 | Larry Ellberger | Director | Sell | 17,728 | $24.50 | $434,336.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Celldex Therapeutics (NASDAQ:CLDX)
Latest Headlines for Celldex Therapeutics (NASDAQ:CLDX)
| Source: |
|
| Date | Headline |
|---|
 | Celldex Therapeutics, Inc. (CLDX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 19 at 2:48 PM |
| $1.17 Million in Sales Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter
www.americanbankingnews.com - August 18 at 11:32 AM |
 | Celldex Therapeutics, Inc. – Value Analysis (NASDAQ:CLDX) : August 17, 2017
finance.yahoo.com - August 16 at 10:44 PM |
| -$0.25 Earnings Per Share Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter
www.americanbankingnews.com - August 16 at 9:42 AM |
| Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 14, 2017
finance.yahoo.com - August 14 at 10:40 PM |
| FY2017 EPS Estimates for Celldex Therapeutics, Inc. (NASDAQ:CLDX) Reduced by Analyst
www.americanbankingnews.com - August 11 at 11:18 AM |
| Edited Transcript of CLDX earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 6:29 PM |
| Celldex Therapeutics, Inc. (CLDX) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
www.americanbankingnews.com - August 9 at 10:48 PM |
 | Celldex Therapeutics' (CLDX) CEO Anthony Marucci on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 9 at 5:26 PM |
 | Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up - Nasdaq
www.nasdaq.com - August 9 at 5:26 PM |
 | Celldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum
www.fool.com - August 9 at 8:15 AM |
 | EARNINGS SUMMARY: Details of Celldex Therapeutics Inc. Q2 Earnings Report
www.rttnews.com - August 8 at 10:03 PM |
| Celldex reports 2Q loss
finance.yahoo.com - August 8 at 10:03 PM |
 | Celldex Reports Second Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - August 8 at 5:00 PM |
| Celldex Reports Second Quarter 2017 Results
finance.yahoo.com - August 8 at 5:00 PM |
| Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 4, 2017
finance.yahoo.com - August 4 at 5:32 PM |
| Critical Comparison: Celldex Therapeutics (NASDAQ:CLDX) and Compugen (CGEN)
www.americanbankingnews.com - August 3 at 8:40 AM |
| What's in the Cards for Celldex (CLDX) this Earnings Season? - Nasdaq
www.nasdaq.com - August 2 at 6:00 PM |
 | Celldex to Report Second Quarter 2017 Financial Results and Host Corporate Update Call
feeds.benzinga.com - August 2 at 12:38 PM |
 | UPDATE: HC Wainwright Assumes Celldex Therapeutics (CLDX) at Buy - StreetInsider.com
www.streetinsider.com - August 1 at 5:56 PM |
| Celldex Therapeutics, Inc. (CLDX) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:16 AM |
| $490,000.00 in Sales Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter
www.americanbankingnews.com - July 31 at 7:33 AM |
| -$0.26 EPS Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter
www.americanbankingnews.com - July 29 at 7:21 AM |
| Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - July 25 at 4:51 PM |
| Better Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics
finance.yahoo.com - July 19 at 6:32 AM |
| Zacks Investment Research Lowers Celldex Therapeutics, Inc. (NASDAQ:CLDX) to Sell
www.americanbankingnews.com - July 17 at 3:26 PM |
| Celldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Down 16.0% in June
www.americanbankingnews.com - July 15 at 7:04 AM |
| Down 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain? - Motley Fool
www.fool.com - July 14 at 7:17 PM |
| Down 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain?
finance.yahoo.com - July 14 at 7:17 PM |
| Celldex Therapeutics, Inc. (NASDAQ:CLDX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - July 11 at 9:38 PM |
| Celldex: Can It Succeed Just Once? - Seeking Alpha
seekingalpha.com - July 7 at 4:36 AM |
| Celldex Therapeutics, Inc. (CLDX) Expected to Announce Quarterly Sales of $490,000.00
www.americanbankingnews.com - July 6 at 9:24 AM |
| Brokerages Expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) Will Post Earnings of -$0.26 Per Share
www.americanbankingnews.com - July 4 at 10:28 PM |
| Celldex Therapeutics, Inc. (NASDAQ:CLDX) Rating Reiterated by Aegis
www.americanbankingnews.com - July 1 at 8:04 AM |
| Celldex Therapeutics, Inc. (CLDX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 30 at 9:11 AM |
| Celldex Therapeutics, Inc. (CLDX) Short Interest Down 9.1% in June
www.americanbankingnews.com - June 29 at 7:25 AM |
| Celldex Therapeutics, Inc. (CLDX) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - June 27 at 5:50 PM |
| Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team
finance.yahoo.com - June 16 at 5:05 PM |
| Why Is Celldex (CLDX) Down 27% Since the Last Earnings Report?
finance.yahoo.com - June 13 at 12:39 PM |
| Celldex Therapeutics, Inc. (CLDX) Short Interest Update
www.americanbankingnews.com - June 12 at 7:18 AM |
| Zacks: Analysts Expect Celldex Therapeutics, Inc. (CLDX) to Post -$0.26 Earnings Per Share
www.americanbankingnews.com - June 8 at 10:18 PM |
| Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting - GlobeNewswire (press release)
globenewswire.com - June 7 at 2:46 PM |
| Here's Why Celldex Therapeutics, Inc. Fell Today - Motley Fool
www.fool.com - June 7 at 2:46 PM |
| Today's Research Reports on Stocks to Watch: Celldex Therapeutics and Pandora Media
finance.yahoo.com - June 7 at 2:46 PM |
| Here's Why Celldex Therapeutics, Inc. Fell Today
finance.yahoo.com - June 6 at 9:37 PM |
| Cowen and Company Reiterates "Buy" Rating for Celldex Therapeutics, Inc. (CLDX)
www.americanbankingnews.com - June 6 at 5:32 PM |
| Celldex Therapeutics to Participate in the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 6 at 4:34 PM |
| Celldex (CLDX) Presents Phase 1 Study of Varlilumab and Opdivo at ASCO
www.streetinsider.com - June 5 at 9:17 PM |
| Here's What Shaved 14% Off Celldex Therapeutics, Inc.'s Stock Price in May
finance.yahoo.com - June 5 at 9:17 PM |
| Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting
finance.yahoo.com - June 5 at 9:17 PM |
Celldex Therapeutics (CLDX) Chart for Tuesday, August, 22, 2017
